Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.57 |
| ▸ | EDNRA | P25101 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.51 |
| ▸ | RXFP4 | Q8TDU9 | 1/20 | 0.51 |
| ▸ | RXFP3 | Q9NSD7 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 8/20 | 0.51 |
| ▸ | IL1RN | P18510 | 3/20 | 0.51 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30721575 | 0.94 | RXFP4 (0.56) | ERAP2EDNRAPTH1RRXFP4RXFP3 | |
| SCHEMBL30093018 | 0.92 | MAGI3 (0.57) | EDNRAMAGI3RXFP1PTH1RRXFP4 | |
| SCHEMBL30130573 | 0.92 | EDNRA (0.59) | ERAP2EDNRAMAGI3RXFP4RXFP3 | |
| SCHEMBL30093082 | 0.92 | EDNRA (0.60) | ERAP2EDNRAMAGI3RXFP4RXFP3 | |
| SCHEMBL30780081 | 0.90 | RXFP1 (0.56) | EDNRARXFP1PTH1RKISS1RKEAP1 | |
| SCHEMBL30586709 | 0.90 | ERAP2 (0.63) | ERAP2MMP1KISS1RIL1RNERAP1 | |
| SCHEMBL30093065 | 0.90 | EDNRA (0.57) | ERAP2EDNRAMAGI3RXFP1PTH1R | |
| SCHEMBL30093075 | 0.90 | KISS1R (0.56) | ERAP2EDNRAMAGI3RXFP1PTH1R | |
| SCHEMBL30093053 | 0.90 | KISS1R (0.56) | ERAP2EDNRAMAGI3RXFP1PTH1R | |
| SCHEMBL30130554 | 0.90 | EDNRA (0.57) | ERAP2EDNRAMAGI3RXFP1PTH1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11860174-B2 | Anti-cannabidiol antibody and uses thereof | Bomi LLC (US) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11860174-B2 | Anti-cannabidiol antibody and uses thereof | CNR2, CNR1, MAG | ERAP2 1908/4885EDNRA 2550/4885MMP1 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.